Aliases & Classifications for Alopecia

MalaCards integrated aliases for Alopecia:

Name: Alopecia 12 73 58 29 6 44 15 70

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:987
ICD9CM 34 704.0
MeSH 44 D000505
NCIt 50 C50575
SNOMED-CT 67 270504008
ICD10 32 L65.9
UMLS via Orphanet 71 C0002170
Orphanet 58 ORPHA79364
UMLS 70 C0002170

Summaries for Alopecia

Disease Ontology : 12 A hypotrichosis that is characterized by a loss of hair from the head or body.

MalaCards based summary : Alopecia is related to alopecia universalis congenita and t-cell immunodeficiency, congenital alopecia, and nail dystrophy, and has symptoms including pruritus and exanthema. An important gene associated with Alopecia is FOXN1 (Forkhead Box N1). The drugs Bimatoprost and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include Hair, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Hair loss, also known as alopecia or baldness, refers to a loss of hair from part of the head or body.... more...

Related Diseases for Alopecia

Diseases in the Alopecia family:

Alopecia, Congenital

Diseases related to Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1065)
# Related Disease Score Top Affiliating Genes
1 alopecia universalis congenita 33.2 HR FOXN1 AIRE
2 t-cell immunodeficiency, congenital alopecia, and nail dystrophy 33.0 FOXN1 ALX4
3 alopecia-intellectual disability syndrome 32.7 LSS AHSG
4 alopecia-mental retardation syndrome 32.4 MBTPS2 LSS AHSG
5 hypotrichosis 31.8 LSS HR GJA1 DCAF17
6 hypotrichosis 11 31.7 RIN2 RBM28 DCAF17
7 atrichia with papular lesions 31.5 VDR HR
8 keratosis 31.1 MBTPS2 KRT14 GJA1 DSP
9 ectodermal dysplasia 30.7 KRT14 GJA1 DSP AIRE
10 palmoplantar keratosis 30.6 SASH1 GJA1 DSP
11 hair disease 30.6 MBTPS2 KRT14 FOXN1 DSP DCAF17 AR
12 acrocephalopolysyndactyly type iii 30.2 RBM28 DCAF17
13 spondylosis 30.0 VDR HTRA1
14 angular cheilitis 29.9 MBTPS2 AIRE
15 skin carcinoma 29.8 VDR SASH1 ODC1 KRT14 AR
16 cardiomyopathy, dilated, with woolly hair and keratoderma 29.7 GJA1 DSP
17 alopecia areata 11.9
18 alopecia, androgenetic, 1 11.7
19 palmoplantar keratoderma and congenital alopecia 1 11.6
20 palmoplantar keratoderma and congenital alopecia 2 11.6
21 woodhouse-sakati syndrome 11.5
22 androgenic alopecia 11.5
23 frontal fibrosing alopecia 11.5
24 alopecia, neurologic defects, and endocrinopathy syndrome 11.5
25 alopecia totalis 11.5
26 mandibulofacial dysostosis with alopecia 11.5
27 central centrifugal cicatricial alopecia 11.5
28 gapo syndrome 11.5
29 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 11.4
30 alopecia-mental retardation syndrome 1 11.4
31 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.4
32 alopecia, psychomotor epilepsy, pyorrhea, and mental subnormality 11.4
33 macs syndrome 11.4
34 alopecia-mental retardation syndrome 4 11.4
35 polyposis, skin pigmentation, alopecia, and fingernail changes 11.4
36 diffuse alopecia areata 11.3
37 vitamin d-dependent rickets, type 2a 11.3
38 ifap syndrome 1, with or without bresheck syndrome 11.3
39 cancer, alopecia, pigment dyscrasia, onychodystrophy, and keratoderma 11.3
40 alopecia-mental retardation syndrome 2 11.3
41 alopecia-contractures-dwarfism-intellectual disability syndrome 11.3
42 crandall syndrome 11.3
43 alopecia-epilepsy-oligophrenia syndrome of moynahan 11.3
44 johnson neuroectodermal syndrome 11.3
45 alopecia-contractures-dwarfism mental retardation syndrome 11.3
46 alopecia areata 1 11.2
47 frontonasal dysplasia 2 11.2
48 satoyoshi syndrome 11.2
49 follicular mucinosis 11.2
50 gomez-lopez-hernandez syndrome 11.2

Graphical network of the top 20 diseases related to Alopecia:



Diseases related to Alopecia

Symptoms & Phenotypes for Alopecia

UMLS symptoms related to Alopecia:


pruritus; exanthema

GenomeRNAi Phenotypes related to Alopecia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.77 GJA1 SASH1
2 Decreased viability GR00249-S 9.77 LSS
3 Decreased viability GR00381-A-1 9.77 LSS
4 Decreased viability GR00386-A-1 9.77 ALX4 FOXN1 LSS ODC1 VDR
5 Decreased viability GR00402-S-2 9.77 DSP EDNRA HTRA1 ODC1
6 Increased CFP-tsO45G cell surface transport GR00360-A-1 8.32 GJA1

MGI Mouse Phenotypes related to Alopecia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.28 AHSG AIRE ALX4 AR DSP EDNRA
2 embryo MP:0005380 10.09 ALX4 AR DSP EDNRA FOXN1 GJA1
3 craniofacial MP:0005382 10.08 ALX4 AR DSP EDNRA GJA1 HR
4 mortality/aging MP:0010768 10.07 AIRE ALX4 AR DSP EDNRA FOXN1
5 digestive/alimentary MP:0005381 10.06 AIRE ALX4 AR DSP EDNRA HR
6 integument MP:0010771 10.02 ALX4 AR DSP EDNRA FOXN1 GJA1
7 hearing/vestibular/ear MP:0005377 9.97 AHSG EDNRA FOXN1 GJA1 HR KRT14
8 muscle MP:0005369 9.76 AHSG ALX4 AR DSP EDNRA FOXN1
9 skeleton MP:0005390 9.61 AHSG ALX4 AR EDNRA FOXN1 GJA1
10 vision/eye MP:0005391 9.32 AIRE ALX4 DSP EDNRA FOXN1 GJA1

Drugs & Therapeutics for Alopecia

Drugs for Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
2
Hydroxychloroquine Approved Phase 4 118-42-3 3652
3
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
4
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
5
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10 Orange Approved Phase 4
11
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
14
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
15
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
16
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Cetirizine Approved Phase 4 83881-51-0 2678
19
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
20
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
21
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
22
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
23 Dermatologic Agents Phase 4
24 Ophthalmic Solutions Phase 4
25 Antimalarials Phase 4
26 Antiprotozoal Agents Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Protective Agents Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Gastrointestinal Agents Phase 4
31 Methylprednisolone Acetate Phase 4
32 Neuroprotective Agents Phase 4
33 Antiemetics Phase 4
34 Antineoplastic Agents, Hormonal Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Sodium Channel Blockers Phase 4
37 Anesthetics, Local Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Respiratory System Agents Phase 4
40 Betamethasone Valerate Phase 4 2152-44-5
41 Betamethasone benzoate Phase 4
42 Betamethasone sodium phosphate Phase 4
43 Betamethasone-17,21-dipropionate Phase 4
44 N-monoacetylcystine Phase 4
45 Neurotransmitter Agents Phase 4
46 Anti-Allergic Agents Phase 4
47 Histamine H1 Antagonists, Non-Sedating Phase 4
48
Histamine Phosphate Phase 4 51-74-1 65513
49 Histamine H1 Antagonists Phase 4
50 Histamine Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 333)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial Unknown status NCT02999737 Phase 4
3 Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation Unknown status NCT03473600 Phase 4 Triamcinolone acetonide injection
4 Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia Unknown status NCT03422640 Phase 4 Apremilast
5 the Effect of Adipose Derived Stem Cells Combined With Platelet Rich Plasma Versus Platelet Rich Plasma Alone on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial Unknown status NCT03388840 Phase 4
6 Open Label Study of Hydroxychloroquine for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
7 An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Completed NCT03521687 Phase 4 Apremilast
8 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
9 Perifollicular Nerves in Alopecia Areata: Response to Topical Capsaicin Completed NCT00176969 Phase 4 Capsaicin
10 Phenotype and Cytokine Production Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Aldara 5% Cream Using Flow Cytometry Completed NCT00176943 Phase 4 Aldara Cream 5%
11 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
12 A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
13 Effectiveness and Safety of Tofacitinib in Patients With Extensive and Recalcitrant Alopecia Areata Completed NCT03800979 Phase 4 Tofacitinib
14 The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial Completed NCT03630198 Phase 4 Corticosteroid with lidocaine;Corticosteroid with normal saline
15 Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial Completed NCT03535233 Phase 4 Triamcinolone Acetonide;Minoxidil 5 % Topical Spray;clobetasol propionate
16 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
17 Minoxidil in Treatment of Androgenetic Alopecia Completed NCT04090801 Phase 4 Topical minoxidil 5% in 90% ethanol and 5% propylene glycol;Topical minoxidil 5% in pure ethanol alone
18 Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study Recruiting NCT04207931 Phase 4 Topical steroid class I-II;Triamcinolone Acetonide;Doxycyline;Minoxidil
19 Efficacy of Fractional CO2 Laser Alone and as Transepidermal Drug Delivery for Different Modalities of Treatment in Alopecia Areata Recruiting NCT04003376 Phase 4 Triamcinolone Acetonide 10mg/mL;vitamin D solution
20 Modified SALT Score for Assessment of Alopecia Areata Recruiting NCT04412148 Phase 4 Triamcinolone Acetonide
21 Efficacy and Tolerability of N-Acetyl- Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men Recruiting NCT04209803 Phase 4 Minoxidil 5% topically and oral NAC 600 mg
22 Does Carboxytherapy Play a Role in Alopecia Areata Either Solely or in Combination? Comparative Study for Treatment of Alopecia Areata Using Carboxytherapy and Intralesional Steroids Active, not recruiting NCT04228029 Phase 4 Intralesional Steroid Injection
23 The Efficacy of Combining 308 Nm-Excimer Light and Topical Steroid in the Treatment of Alopecia Areata Not yet recruiting NCT04793945 Phase 4
24 Topical Cetirizine Gel Versus Minoxidil 5% Gel in Treatment of Androgenetic Alopecia Not yet recruiting NCT04293822 Phase 4 Cetirizine;Minoxidil
25 A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata Terminated NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
26 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
27 BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA Unknown status NCT01655108 Phase 3 Minoxidil;Saline
28 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
29 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
30 Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
31 A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness Completed NCT03004469 Phase 3 P-3074;Finasteride;P-3074 Vehicle;Finasteride Placebo
32 An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V) Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
33 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5% Minoxidil Foam vs. Vehicle in Females for the Treatment of Female Pattern Hair Loss (Androgenetic Alopecia) Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
34 Evaluating the Efficacy of Topical Herbal Solution on the Treatment of Androgenetic Alopecia and Comparison With Minoxidil 5%: A Double-Blind, Randomized, Clinical Trial Study Completed NCT03753113 Phase 3 Topical Herbal Solution;Topical Minoxidil 5%
35 A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
36 A Double-Blind, Randomized, Placebo-Controlled Trial of the Efficacy and Safety of 5 Percent Minoxidil Foam in the Treatment of Androgenetic Alopecia in Males Completed NCT00151515 Phase 3 minoxidil
37 A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
38 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia Completed NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
39 A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
40 A Randomized Controlled Trial of Clobetasol Propionate 0.05% Cream Versus Hydrocortisone 1% Cream in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
41 A Phase 3 Multi-Center Parallel Design Clinical Trial to Compare the Efficacy and Safety of 5 % Minoxidil Foam vs. 2 % Minoxidil Solution in Females for the Treatment of Female Pattern Hair Loss - Androgenetic Alopecia (MINALO3004, NCT01145625) Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
42 Efficacy of 3% Minoxidil Versus Combined 3% Minoxidil and 0.1% Finasteride for Male Pattern Hair Loss: a Randomized, Double-blinded, Comparative Study Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
43 RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE) Completed NCT02037191 Phase 3 Methotrexate;Placebo
44 A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
45 A Prospective, Randomized, Controlled, Double-Blind Study That Evaluates the Safety and Efficacy of Three Active REVIAN Caps Versus a Non-Active REVIAN Cap (Sham) in Participants With Pattern Hair Loss (Androgenic Alopecia) Completed NCT04019795 Phase 3
46 TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2 Completed NCT02557074 Phase 3 IL2;placebo
47 Investigator-initiated Single Blind, Two-armed, Randomized Phase 3 Clinical Trial to Compare Efficacy of 5% Minoxidil Topical Foam (5% Mtf) Once Daily Versus 2% Minoxidil Topical Solution (2% Mts) Twice Daily in Application on Females With Slightly to Moderate Androgenetic Alopecia Concerning Hair Volume Completed NCT00958750 Phase 3 minoxidil
48 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
49 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
50 The Derm Aid Study Completed NCT04249128 Phase 3

Search NIH Clinical Center for Alopecia

Inferred drug relations via UMLS 70 / NDF-RT 51 :


D-BIOTIN
Finasteride
Minoxidil

Cochrane evidence based reviews: alopecia

Genetic Tests for Alopecia

Genetic tests related to Alopecia:

# Genetic test Affiliating Genes
1 Alopecia 29

Anatomical Context for Alopecia

MalaCards organs/tissues related to Alopecia:

40
Prostate, Skin, Ovary, Breast, T Cells, Lung, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Alopecia:
# Tissue Anatomical CompartmentCell Relevance
1 Hair Hair Follicle Fetal Hair Placode Cells Affected by disease
2 Hair Hair Follicle Fetal Matrix Cells Affected by disease
3 Hair Dermal Papilla Guard Dermal Papilla Cells Affected by disease
4 Hair Hair Follicle Primary Hair Placode Cells Affected by disease

Publications for Alopecia

Articles related to Alopecia:

(show top 50) (show all 17732)
# Title Authors PMID Year
1
Dihydrotestosterone-induced hair regrowth inhibition by activating androgen receptor in C57BL6 mice simulates androgenetic alopecia. 61
33517191 2021
2
Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT. 61
33315676 2021
3
HaCaT‑conditioned medium supplemented with the small molecule inhibitors SB431542 and CHIR99021 and the growth factor PDGF‑AA prevents the dedifferentiation of dermal papilla cells in vitro. 61
33760132 2021
4
Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists. 61
33215562 2021
5
Implication of Human Bacterial Gut Microbiota on Immune-Mediated and Autoimmune Dermatological Diseases and Their Comorbidities: A Narrative Review. 61
33507493 2021
6
Psychiatric Basics of Alopecia Areata in Pediatric Patients: Evaluation of Emotion Dysregulation, Somatization, Depression and Anxiety Levels. 61
33797195 2021
7
Inhibition of pyruvate oxidation as a versatile stimulator of the hair cycle in models of alopecia. 61
33739490 2021
8
Clinical and molecular evaluation of 13 Brazilian patients with Gomez-López-Hernández syndrome. 61
33381921 2021
9
Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients. 61
33554715 2021
10
Italian Survey for the Evaluation of the Effects of Coronavirus Disease 2019 (COVID-19) Pandemic on Alopecia Areata Recurrence. 61
33580408 2021
11
Comparison of patients' diagnoses in a dermatology outpatient clinic during the COVID-19 pandemic period and pre-pandemic period. 61
33332694 2021
12
Anti-androgenetic alopecia effect of policosanol from Chinese wax by regulating abnormal hormone levels to suppress premature hair follicle entry into the regression phase. 61
33485069 2021
13
Microneedling in androgenetic alopecia; comparing two different depths of microneedles. 61
32897622 2021
14
Autologous activated platelet-rich plasma in hair growth: A pilot study in male androgenetic alopecia with in vitro bioactivity investigation. 61
32888247 2021
15
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. 61
33135263 2021
16
Implications of cigarette smoking on early-onset androgenetic alopecia: A cross-sectional Study. 61
32946667 2021
17
Platelet-rich plasma has a place in the treatment of androgenetic alopecia. 61
33253835 2021
18
Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. 61
33253848 2021
19
Platelet-rich plasma lacks evidence of clinically significant improvement in androgenetic alopecia. 61
33253851 2021
20
Immune privilege of skin stem cells: What do we know and what can we learn? 61
33103270 2021
21
Therapeutic implications of topical cetirizine 1% in treatment of male androgenetic alopecia: A case-controlled study. 61
33417284 2021
22
Telomere Dynamics and Telomerase in the Biology of Hair Follicles and their Stem Cells as a Model for Aging Research. 61
33509633 2021
23
Lichen planopilaris in men: a retrospective clinicopathologic study of 19 patients. 61
33128471 2021
24
[Neuroendorine paraneoplastic syndromes]. 61
33661337 2021
25
Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer. 61
33797651 2021
26
Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer? 61
33512741 2021
27
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. 61
33168656 2021
28
Scalp cooling in breast cancer patients treated with docetaxel-cyclophosphamide: patient- and nurse-reported results. 61
33452953 2021
29
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer. 61
33168657 2021
30
Prospective study of hair recovery after (neo)adjuvant chemotherapy with scalp cooling in Japanese breast cancer patients. 61
33797582 2021
31
Cell cycle regulation in human hair follicle dermal papilla cells using nonthermal atmospheric pressure plasma-activated medium. 61
33787651 2021
32
Temporal triangular alopecia confined to the frontal scalp. 61
33599992 2021
33
Preventive effect of edaravone ointment on cyclophosphamide-chemotherapy induced alopecia. 61
33797584 2021
34
Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. 61
33137442 2021
35
Comment on: Risk factors for frontal fibrosing alopecia: A case-control study in a multiracial population. 61
33253842 2021
36
Regarding methodologic concerns in clinical studies on frontal fibrosing alopecia. 61
33253845 2021
37
Blockade of IL-7 signaling suppresses inflammatory responses and reverses alopecia areata in C3H/HeJ mice. 61
33811067 2021
38
Concurrent Chemo-Proton Therapy Using Adaptive Planning for Unresectable Stage 3 Non-Small Cell Lung Cancer: A Phase 2 Study. 61
33227444 2021
39
Posttraumatic Stress Disorder and the Associated Risk of Autoimmune Skin Diseases: A Nationwide Population-Based Cohort Study. 61
33587564 2021
40
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 61
33608949 2021
41
Transverse sectioning in the evaluation of skin biopsy specimens from alopecic dogs. 61
33047299 2021
42
Regional alopecia and dermatitis due to Lodderomyces elongisporus in a North American porcupine (Erethizon dorsatum). 61
33185315 2021
43
Female Pattern Hair Loss: Why the Follicular Unit Transplantation Surgical Technique Remains a Good Option. 61
33710162 2021
44
The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. 61
33811438 2021
45
Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations. 61
32941917 2021
46
Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study. 61
33751494 2021
47
Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan. 61
33464474 2021
48
Efficacy of antihistamines in combination with topical corticosteroid and superficial cryotherapy for treatment of alopecia areata: A retrospective cohort study. 61
32682023 2021
49
Permanent hair wavings: What dermatologists should know? 61
32813907 2021
50
Fat Grafting in Radiation-Induced Soft-Tissue Injury: A Narrative Review of the Clinical Evidence and Implications for Future Studies. 61
33776031 2021

Variations for Alopecia

ClinVar genetic disease variations for Alopecia:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SASH1 NM_015278.5(SASH1):c.1849G>A (p.Glu617Lys) SNV Likely pathogenic 156162 rs587781245 GRCh37: 6:148855021-148855021
GRCh38: 6:148533885-148533885
2 overlap with 9 genes GRCh37/hg19 18p11.32-11.31(chr18:1345040-3479168) copy number loss Uncertain significance 523239 GRCh37: 18:1345040-3479168
GRCh38:

Expression for Alopecia

Search GEO for disease gene expression data for Alopecia.

Pathways for Alopecia

GO Terms for Alopecia

Cellular components related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fascia adherens GO:0005916 8.62 GJA1 DSP

Biological processes related to Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 9.33 VDR ALX4 AHSG
2 decidualization GO:0046697 9.26 VDR GJA1
3 epidermis development GO:0008544 9.13 KRT14 FOXN1 DSP
4 thymus epithelium morphogenesis GO:0097536 8.62 FOXN1 AIRE

Sources for Alopecia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....